CLIF-C Score and CLIF-SOFA Score
The CLIF-C ACLF score is a prognostic scoring system that combines organ failure assessment (CLIF-C OF score) with age and white blood cell count to predict mortality in patients with acute-on-chronic liver failure (ACLF), while CLIF-SOFA is a modified Sequential Organ Failure Assessment score adapted specifically for end-stage liver disease patients to assess organ dysfunction across six organ systems.
CLIF-SOFA (Chronic Liver Failure-Sequential Organ Failure Assessment)
CLIF-SOFA is a modified version of the general ICU SOFA score, specifically designed for patients with cirrhosis and end-stage liver disease 1, 2, 3.
Key components assessed:
- Liver function (bilirubin, INR)
- Kidney function (creatinine or need for renal replacement therapy)
- Brain function (hepatic encephalopathy grade/Glasgow Coma Scale)
- Coagulation (INR)
- Circulation (mean arterial pressure, vasopressor requirements)
- Respiration (PaO2/FiO2 ratio, mechanical ventilation)
The CLIF-SOFA score evaluates these six organ systems to identify organ failures in critically ill cirrhotic patients 2, 3. Research demonstrates it has excellent discriminatory power (AUROC 0.900) for predicting 6-month mortality in ICU patients with cirrhosis 2.
CLIF-C ACLF Score (CLIF Consortium ACLF Score)
The CLIF-C ACLF score is the recommended prognostic tool for patients with ACLF, superior to MELD, MELD-Na, and Child-Pugh scores 1.
Score components:
- CLIF-C OF score (organ failure assessment based on CLIF-SOFA)
- Age
- White blood cell count
The score ranges from 0-100 and was developed and validated specifically for ACLF patients 4, 5.
Performance Characteristics
The CLIF-C ACLF score demonstrates superior predictive accuracy compared to traditional liver disease scores 4:
- 28-day mortality: C-index 0.76 (vs. MELD 0.69, MELD-Na 0.68, Child-Pugh 0.67; p <0.001 for all)
- 90-day mortality: C-index 0.73 (vs. MELD 0.66, MELD-Na 0.66, Child-Pugh 0.66; p <0.001 for all)
The score has been validated worldwide in multiple single and multicenter studies 4.
Clinical Application
Dynamic Assessment is Critical
Serial calculation of the CLIF-C ACLF score at days 3-7 after diagnosis is essential for accurate prognostication 1. This dynamic approach is superior to single time-point assessment because:
- Patients with ACLF-3 (≥3 organ failures) who improve by day 3 have 40% 90-day mortality versus 79% in those who don't improve 1
- Sequential assessment identifies patients who may benefit from early liver transplantation versus those where further treatment may be futile 1
ACLF Grading Based on Organ Failures
- ACLF-1: Single renal failure OR single non-renal organ failure with renal dysfunction and/or cerebral dysfunction (28-day mortality ~23%)
- ACLF-2: Two organ failures (28-day mortality ~32-46%)
- ACLF-3: Three to six organ failures (28-day mortality ~74%) 3
Guideline Recommendations
Both EASL (2023) and AASLD (2024) guidelines strongly recommend:
- Use CLIF-C ACLF score over MELD/MELD-Na for prognostication in critically ill cirrhotic patients with ACLF 1, 4
- Calculate scores serially (not just at admission) to assess response to intervention 1, 4
- Use CLIF-C OF criteria to diagnose ACLF and define organ failures 4
Important Caveats
- In ICU settings, CLIF-C ACLF score performs similarly to general ICU scores (APACHE III), but has the advantage of being liver-disease specific 4, 6
- The score has some subjectivity in variables like hepatic encephalopathy grading and timing of vasopressor initiation 1
- A CLIF-SOFA score >11 at ICU admission predicts significantly worse 6-month survival 2
- Adding lactate to CLIF-C ACLF improves predictive accuracy for 28-day, 90-day, and 1-year mortality 1